274
Participants
Start Date
November 6, 2013
Primary Completion Date
March 16, 2018
Study Completion Date
March 16, 2018
Secukinumab
Group 1: secukinumab 75 mg plus placebo 150 mg or Group 2 secukinumab 150 mg plus placebo 75m dosed every four weeks Week 104E1 through Week 152. Starting on Week 156 (after unblinding), only secukinumab 75 mg or 150 mg were dosed. Secukinumab in PFS for s.c. self-administration Q4W
Placebo (Pbo)
Group 1: secukinumab 75 mg plus placebo 150 mg or Group 2 secukinumab 150 mg plus placebo 75m dosed every four weeks Week 104E1 through Week 152. Starting on Week 156 (after unblinding), only secukinumab 75 mg or 150 mg were dosed. Secukinumab in PFS for s.c. self-administration Q4W
Novartis Investigative Site, Jesus Maria
Novartis Investigative Site, La Victoria
Novartis Investigative Site, Pueblo Libre
Novartis Investigative Site, San Isidro
Novartis Investigative Site, Surquillo
Novartis Investigative Site, Brussels
Novartis Investigative Site, Sofia
Novartis Investigative Site, Sofia
Novartis Investigative Site, Leuven
Novartis Investigative Site, Genk
Novartis Investigative Site, Plovdiv
Novartis Investigative Site, Plovdiv
Novartis Investigative Site, Burgas
Novartis Investigative Site, Ghent
Novartis Investigative Site, Torino
Novartis Investigative Site, Berlin
Novartis Investigative Site, Duncansville
Novartis Investigative Site, Mexicali
Novartis Investigative Site, Hamburg
Novartis Investigative Site, Brescia
Novartis Investigative Site, Gaziantep
Novartis Investigative Site, Bordeaux
Novartis Investigative Site, Izmir
Novartis Investigative Site, Kingsport
Novartis Investigative Site, Jackson
Novartis Investigative Site, Magdeburg
Novartis Investigative Site, Taichung
Novartis Investigative Site, Guadalajara
Novartis Investigative Site, Herne
Novartis Investigative Site, Cologne
Novartis Investigative Site, Siena
Novartis Investigative Site, Monterrey
Novartis Investigative Site, Paris
Novartis Investigative Site, Kaohsiung City
Novartis Investigative Site, Limoges
Novartis Investigative Site, Palermo
Novartis Investigative Site, Nuremberg
Novartis Investigative Site, Erlangen
Novartis Investigative Site, Catania
Novartis Investigative Site, Portland
Novartis Investigative Site, Spokane
Novartis Investigative Site, Moscow
Novartis Investigative Site, Yaroslavl
Novartis Investigative Site, Saint Petersburg
Novartis Investigative Site, Tula
Novartis Investigative Site, Yekaterinburg
Novartis Investigative Site, Yekaterinburg
Novartis Investigative Site, Winnipeg
Novartis Investigative Site, St. John's
Novartis Investigative Site, Culiacán
Novartis Investigative Site, Amsterdam
Novartis Investigative Site, Utrecht
Novartis Investigative Site, London
Novartis Investigative Site, Cambridge
Novartis Investigative Site, Newcastle upon Tyne
Novartis Investigative Site, Wolverhampton
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY